Skip to content

Stereotaxis STXS Share-Based Payment - Unrecognized Cost of Nonvested Awards

Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies

Microbot Medical logo
Microbot MedicalMBOT
$1.11M+20.4%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$18.4M-13.2%

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Cash & equivalents$14.6M+36.7%
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-8.0%
Enterprise value$158.77M-12.3%
P/S5.4×-0.4×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's share-based payment - unrecognized cost of nonvested awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's share-based payment - unrecognized cost of nonvested awards?
Stereotaxis (STXS) reported share-based payment - unrecognized cost of nonvested awards of $2M in Q1 2026.
How has Stereotaxis's share-based payment - unrecognized cost of nonvested awards changed year-over-year?
Stereotaxis's share-based payment - unrecognized cost of nonvested awards decreased by 13.0% year-over-year, from $2.3M to $2M.
What is the long-term trend for Stereotaxis's share-based payment - unrecognized cost of nonvested awards?
Over 5 years (2020 to 2025), Stereotaxis's share-based payment - unrecognized cost of nonvested awards has grown at a -9.0% compound annual growth rate (CAGR), from $3.2M to $2M.
What does share-based payment - unrecognized cost of nonvested awards mean?
This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.